首页> 外文期刊>Biochimie >Binding of antitumor tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen to human serum albumin
【24h】

Binding of antitumor tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen to human serum albumin

机译:抗肿瘤他莫昔芬及其代谢物4-羟基他莫昔芬和内皮西芬与人血清白蛋白的结合

获取原文
获取原文并翻译 | 示例
       

摘要

Tamoxifen is extensively metabolized, and several metabolites have been detected in human serum. The aim of this study was to examine the interaction of human serum albumin (HSA) with tamoxifen and its metabolites 4-hydroxytamoxifen and endoxifen at physiological conditions, using constant protein concentration and various drug contents. FTIR, UV-Visible, CD and fluorescence spectroscopic methods as well as molecular modeling were used to analyse drug binding mode, the binding constant and the effects of drug complexation on HSA stability and conformation. Structural analysis showed that tamoxifen and its metabolites bound HSA via both hydrophobic and hydrophilic interactions with overall binding constants of K_(tam)= 1.8 (±0.2) x 10~4 M~(-1), K_4-hydroxytam = 1-8 (±0.4) x 104 NT1 and K_(endox)= 2.0 (±0.5) ×10~4 M~_(-1). The number of bound drugs per protein is 1.2 (tamoxifen), 1.7 (4-hydroxitamoxifen) and 1.0 (endoxifen). Structural modeling showed the participation of several amino acid residues in drug —HSA complexation, with extended H-bonding network. HSA conformation was altered by tamoxifen and its metabolites with a major reduction of a-helix and an increase in [5-sheet, random coil and turn structures, indicating a partial protein unfolding. Our results suggest that serum albumins can act as carrier proteins for tamoxifen and its metabolites in delivering them to target tissues.
机译:他莫昔芬被广泛代谢,在人血清中已检测到几种代谢物。这项研究的目的是在恒定的蛋白质浓度和不同的药物含量下,在生理条件下研究人血清白蛋白(HSA)与他莫昔芬及其代谢产物4-羟基他莫昔芬和endoxifen的相互作用。 FTIR,UV-Visible,CD和荧光光谱法以及分子模型被用来分析药物结合模式,结合常数以及药物络合对HSA稳定性和构象的影响。结构分析表明他莫昔芬及其代谢产物通过疏水和亲水相互作用与HSA结合,总结合常数为K_(tam)= 1.8(±0.2)x 10〜4 M〜(-1),K_4-hydroxytam = 1-8( ±0.4)x 104 NT1和K_(endox)= 2.0(±0.5)×10〜4 M〜_(-1)。每个蛋白结合药物的数量为1.2(他莫昔芬),1.7(4-羟西莫昔芬)和1.0(内氧芬)。结构模型表明药物-HSA络合中具有多个氨基酸残基,并具有扩展的H键网络。他莫昔芬及其代谢物改变了HSA构象,α-螺旋显着减少,[5-sheet,无规卷曲和转向结构增加,表明部分蛋白质解折叠。我们的结果表明,血清白蛋白可以作为他莫昔芬及其代谢产物的载体蛋白,将其输送到靶组织。

著录项

  • 来源
    《Biochimie》 |2011年第7期|p.1089-1101|共13页
  • 作者单位

    Departement de Chimie-Biologie, Universite du Quebec a Trois-Rivieres, C.P. 500, Trois-Rivieres, Quebec C9A 5H7, Canada;

    Departement de Chimie-Biologie, Universite du Quebec a Trois-Rivieres, C.P. 500, Trois-Rivieres, Quebec C9A 5H7, Canada;

    Chemical Synthesis Core Facility, Mayo Clinic, Jacksonville, FL 32224, USA;

    Chemical Synthesis Core Facility, Mayo Clinic, Jacksonville, FL 32224, USA;

    Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903 USA,The Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ 08903 USA;

    Departement de Chimie-Biologie, Universite du Quebec a Trois-Rivieres, C.P. 500, Trois-Rivieres, Quebec C9A 5H7, Canada;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    tamoxifen; endoxifen; hsa; binding mode; secondary structure; ftir; cd; fluorescence spectroscopy;

    机译:他莫昔芬;恩多昔芬;hsa;结合模式;二级结构;ftir;cd;荧光光谱;
  • 入库时间 2022-08-18 01:23:57

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号